{
    "abstract": "African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides. AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and the immunogenicity of each was studied by immunization of guinea pigs with single VP2 as well as with cocktails of VP2 proteins. Homologous neutralizing antibodies measured by 50% plaque reduction assay showed varying degrees (from 37 to 1365) of titers for different VP2 proteins. A low cross-neutralizing antibody titer was found for genetically related AHSV serotypes. Immunization with VP2 cocktails containing equal amounts of each of the VP2 proteins also triggered neutralizing antibodies albeit to lower titers (4-117) to each of the serotypes in the cocktail. This study is a first step to develop a VP2 subunit vaccine for AHS and our results indicate that VP2 subunit vaccines are feasible individually or in a multi-serotype cocktail. \u00a9 2014 The Authors.",
    "bib_entries": {
        "bib0005": {
            "authors": [
                {
                    "first": "Philip Scott",
                    "initial": "P.S.",
                    "last": "Mellor"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Hamblin"
                }
            ],
            "doi": "10.1051/vetres:2004021",
            "firstpage": "445",
            "issn": "09284249",
            "lastpage": "466",
            "pmid": "15236676",
            "pub_year": 2004,
            "title": "African horse sickness",
            "volume": "35"
        },
        "bib0010": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Bouayoune"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Touti"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "El Hasnaoui"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Baylis"
                },
                {
                    "first": "P. S.",
                    "initial": "P.S.",
                    "last": "Mellor"
                }
            ],
            "firstpage": "113",
            "issn": "09391983",
            "lastpage": "125",
            "pmid": "9785501",
            "pub_year": 1998,
            "title": "The Culicoides vectors of African horse sickness virus in Morocco: Distribution and epidemiological implications",
            "volume": "1998"
        },
        "bib0015": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Capela"
                },
                {
                    "first": "Bethan V.",
                    "initial": "B.V.",
                    "last": "Purse"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Pena"
                },
                {
                    "first": "E. J.",
                    "initial": "E.J.",
                    "last": "Wittman"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Margarita"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Capela"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rom\u00e3o"
                },
                {
                    "first": "P. S.",
                    "initial": "P.S.",
                    "last": "Mellor"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Baylis"
                }
            ],
            "doi": "10.1046/j.1365-2915.2003.00419.x",
            "firstpage": "165",
            "issn": "0269283X",
            "lastpage": "177",
            "pmid": "12823834",
            "pub_year": 2003,
            "title": "Spatial distribution of Culicoides species in Portugal in relation to the transmission of African horse sickness and bluetongue viruses",
            "volume": "17"
        },
        "bib0020": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Huismans"
                },
                {
                    "first": "N. T.",
                    "initial": "N.T.",
                    "last": "van Der Walt"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Cloete"
                },
                {
                    "first": "B. J.",
                    "initial": "B.J.",
                    "last": "Erasmus"
                }
            ],
            "doi": "10.1016/0042-6822(87)90326-6",
            "firstpage": "172",
            "issn": "00426822",
            "lastpage": "179",
            "pmid": "3029956",
            "pub_year": 1987,
            "title": "Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep",
            "volume": "157"
        },
        "bib0025": {
            "authors": [
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Roy"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Urakawa"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Van Dijk"
                },
                {
                    "first": "B. J.",
                    "initial": "B.J.",
                    "last": "Erasmus"
                }
            ],
            "firstpage": "1998",
            "issn": "0022538X",
            "lastpage": "2003",
            "pmid": "2157868",
            "pub_year": 1990,
            "title": "Recombinant virus vaccine for bluetongue disease in sheep",
            "volume": "64"
        },
        "bib0030": {
            "authors": [
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "Wade-Evans"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Pullen"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Hamblin"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "O'Hara"
                },
                {
                    "first": "J. N.",
                    "initial": "J.N.",
                    "last": "Burroughs"
                },
                {
                    "first": "P. P.C.",
                    "initial": "P.P.C.",
                    "last": "Mertens"
                }
            ],
            "doi": "10.1099/0022-1317-78-7-1611",
            "firstpage": "1611",
            "issn": "00221317",
            "lastpage": "1616",
            "pmid": "9225037",
            "pub_year": 1997,
            "title": "African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge",
            "volume": "78"
        },
        "bib0035": {
            "authors": [
                {
                    "first": "Linda D.",
                    "initial": "L.D.",
                    "last": "Jones"
                },
                {
                    "first": "Trevor",
                    "initial": "T.",
                    "last": "Williams"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Bishop"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Roy"
                }
            ],
            "firstpage": "297",
            "issn": "1071412X",
            "lastpage": "301",
            "pmid": "9144367",
            "pub_year": 1997,
            "title": "Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection",
            "volume": "4"
        },
        "bib0040": {
            "authors": [
                {
                    "first": "Marion",
                    "initial": "M.",
                    "last": "Andrew"
                },
                {
                    "first": "Pam",
                    "initial": "P.",
                    "last": "Whiteley"
                },
                {
                    "first": "Vijaya",
                    "initial": "V.",
                    "last": "Janardhana"
                },
                {
                    "first": "Zelia",
                    "initial": "Z.",
                    "last": "Lobato"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Gould"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Coupar"
                }
            ],
            "doi": "10.1016/0165-2427(94)05410-T",
            "firstpage": "311",
            "issn": "01652427",
            "lastpage": "322",
            "pmid": "8571549",
            "pub_year": 1995,
            "title": "Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus",
            "volume": "47"
        },
        "bib0045": {
            "authors": [
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Janardhana"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Andrew"
                },
                {
                    "first": "Z. I.P.",
                    "initial": "Z.I.P.",
                    "last": "Lobato"
                },
                {
                    "first": "B. E.H.",
                    "initial": "B.E.H.",
                    "last": "Coupar"
                }
            ],
            "doi": "10.1053/rvsc.1999.0306",
            "firstpage": "213",
            "issn": "00345288",
            "lastpage": "221",
            "pmid": "10607500",
            "pub_year": 1999,
            "title": "The ovine cytotoxic T lymphocyte responses to bluetongue virus",
            "volume": "67"
        },
        "bib0050": {
            "authors": [
                {
                    "first": "C. A.L.",
                    "initial": "C.A.L.",
                    "last": "Oura"
                },
                {
                    "first": "P. A.S.",
                    "initial": "P.A.S.",
                    "last": "Ivens"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Bachanek-Bankowska"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bin-Tarif"
                },
                {
                    "first": "D. B.",
                    "initial": "D.B.",
                    "last": "Jallow"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Sailleau"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Maan"
                },
                {
                    "first": "P. C.",
                    "initial": "P.C.",
                    "last": "Mertens"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Batten"
                }
            ],
            "doi": "10.1017/S095026881100080X",
            "firstpage": "462",
            "issn": "09502688",
            "lastpage": "465",
            "pmid": "21733265",
            "pub_year": 2012,
            "title": "African horse sickness in the Gambia: Circulation of a live-attenuated vaccine-derived strain",
            "volume": "140"
        },
        "bib0055": {
            "authors": [
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Ozawa"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Bahrami"
                }
            ],
            "firstpage": "311",
            "issn": "03165957",
            "lastpage": "314",
            "pmid": "4226381",
            "pub_year": 1966,
            "title": "African horse-sickness killed-virus tissue culture vaccine.",
            "volume": "30"
        },
        "bib0060": {
            "authors": [
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "House"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Lombard"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Dubourget"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "House"
                },
                {
                    "first": "Charles A.",
                    "initial": "C.A.",
                    "last": "Mebus"
                }
            ],
            "doi": "10.1016/0264-410X(94)90052-3",
            "firstpage": "142",
            "issn": "0264410X",
            "lastpage": "144",
            "pmid": "8147096",
            "pub_year": 1994,
            "title": "Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine",
            "volume": "12"
        },
        "bib0065": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Romito"
                }
            ],
            "firstpage": "139",
            "issn": "00302465",
            "lastpage": "144",
            "pmid": "10486832",
            "pub_year": 1999,
            "title": "Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus",
            "volume": "66"
        },
        "bib0070": {
            "authors": [
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Roy"
                },
                {
                    "first": "David H.L.",
                    "initial": "D.H.L.",
                    "last": "Bishop"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Howard"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Aitchison"
                },
                {
                    "first": "Baltus",
                    "initial": "B.",
                    "last": "Erasmus"
                }
            ],
            "doi": "10.1099/0022-1317-77-9-2053",
            "firstpage": "2053",
            "issn": "00221317",
            "lastpage": "2057",
            "pmid": "8811002",
            "pub_year": 1996,
            "title": "Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge",
            "volume": "77"
        },
        "bib0075": {
            "authors": [
                {
                    "first": "Alan J.",
                    "initial": "A.J.",
                    "last": "Guthrie"
                },
                {
                    "first": "Melvyn",
                    "initial": "M.",
                    "last": "Quan"
                },
                {
                    "first": "Carina W.",
                    "initial": "C.W.",
                    "last": "Lourens"
                },
                {
                    "first": "Jean Christophe",
                    "initial": "J.C.",
                    "last": "Audonnet"
                },
                {
                    "first": "Jules M.",
                    "initial": "J.M.",
                    "last": "Minke"
                },
                {
                    "first": "Jiansheng",
                    "initial": "J.",
                    "last": "Yao"
                },
                {
                    "first": "Ling",
                    "initial": "L.",
                    "last": "He"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Nordgren"
                },
                {
                    "first": "Ian A.",
                    "initial": "I.A.",
                    "last": "Gardner"
                },
                {
                    "first": "N. James",
                    "initial": "N.J.",
                    "last": "MacLachlan"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.05.044",
            "firstpage": "4434",
            "issn": "0264410X",
            "lastpage": "4438",
            "pmid": "19490959",
            "pub_year": 2009,
            "title": "Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus",
            "volume": "27"
        },
        "bib0080": {
            "authors": [
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Chiam"
                },
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Sharp"
                },
                {
                    "first": "Sushila",
                    "initial": "S.",
                    "last": "Maan"
                },
                {
                    "first": "Shujing",
                    "initial": "S.",
                    "last": "Rao"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Mertens"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Blacklaws"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Davis-Poynter"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wood"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Castillo-Olivares"
                }
            ],
            "doi": "10.1371/journal.pone.0005997",
            "issn": "19326203",
            "pmid": "19543394",
            "pub_year": 2009,
            "title": "Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)",
            "volume": "4"
        },
        "bib0085": {
            "authors": [
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Castillo-Olivares"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Calvo-Pinilla"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Casanova"
                },
                {
                    "first": "Katarzyna",
                    "initial": "K.",
                    "last": "Bachanek-Bankowska"
                },
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Chiam"
                },
                {
                    "first": "Sushila",
                    "initial": "S.",
                    "last": "Maan"
                },
                {
                    "first": "Jose Maria",
                    "initial": "J.M.",
                    "last": "Nieto"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Ortego"
                },
                {
                    "first": "Peter Paul Clement",
                    "initial": "P.P.C.",
                    "last": "Mertens"
                }
            ],
            "doi": "10.1371/journal.pone.0016503",
            "issn": "19326203",
            "pmid": "21298069",
            "pub_year": 2011,
            "title": "A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model",
            "volume": "6"
        },
        "bib0090": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Scanlen"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Paweska"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Verschoor"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Van Dijk"
                }
            ],
            "doi": "10.1016/S0264-410X(01)00445-5",
            "firstpage": "1079",
            "issn": "0264410X",
            "lastpage": "1088",
            "pmid": "11803068",
            "pub_year": 2002,
            "title": "The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant",
            "volume": "20"
        },
        "bib0095": {
            "authors": [
                {
                    "first": "Berta",
                    "initial": "B.",
                    "last": "Alberca"
                },
                {
                    "first": "Katarzyna",
                    "initial": "K.",
                    "last": "Bachanek-Bankowska"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Cabana"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Calvo-Pinilla"
                },
                {
                    "first": "Elisenda",
                    "initial": "E.",
                    "last": "Viaplana"
                },
                {
                    "first": "Lorraine",
                    "initial": "L.",
                    "last": "Frost"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Gubbins"
                },
                {
                    "first": "Alicia",
                    "initial": "A.",
                    "last": "Urniza"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Mertens"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Castillo-Olivares"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.04.036",
            "firstpage": "3670",
            "issn": "0264410X",
            "lastpage": "3674",
            "pmid": "24837765",
            "pub_year": 2014,
            "title": "Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge",
            "volume": "32"
        },
        "bib0100": {
            "authors": [
                {
                    "first": "T. G.",
                    "initial": "T.G.",
                    "last": "Burrage"
                },
                {
                    "first": "Rosalie",
                    "initial": "R.",
                    "last": "Trevejo"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Stone-Marschat"
                },
                {
                    "first": "W. W.",
                    "initial": "W.W.",
                    "last": "Laegreid"
                }
            ],
            "doi": "10.1006/viro.1993.1537",
            "firstpage": "799",
            "issn": "00426822",
            "lastpage": "803",
            "pub_year": 1993,
            "title": "Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2",
            "volume": "196"
        },
        "bib0105": {
            "authors": [
                {
                    "first": "Jorge L.",
                    "initial": "J.L.",
                    "last": "Martinez-Torrecuadrada"
                },
                {
                    "first": "Hiroyuki",
                    "initial": "H.",
                    "last": "Iwata"
                },
                {
                    "first": "Angel A.",
                    "initial": "A.A.",
                    "last": "Venteo"
                },
                {
                    "first": "Ignacio I.",
                    "initial": "I.I.",
                    "last": "Casal"
                },
                {
                    "first": "Polly P.",
                    "initial": "P.P.",
                    "last": "Roy"
                }
            ],
            "doi": "10.1006/viro.1994.1351",
            "firstpage": "348",
            "issn": "00426822",
            "lastpage": "359",
            "pub_year": 1994,
            "title": "Expression and characterization of the two outer capsid proteins of African horsesickness virus: The role of VP2 in virus neutralization",
            "volume": "202"
        },
        "bib0110": {
            "authors": [
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Stone-Marschat"
                },
                {
                    "first": "S. R.",
                    "initial": "S.R.",
                    "last": "Moss"
                },
                {
                    "first": "T. G.",
                    "initial": "T.G.",
                    "last": "Burrage"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Barber"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Roy"
                },
                {
                    "first": "W. W.",
                    "initial": "W.W.",
                    "last": "Laegreid"
                }
            ],
            "doi": "10.1006/viro.1996.0304",
            "firstpage": "219",
            "issn": "00426822",
            "lastpage": "222",
            "pmid": "8659117",
            "pub_year": 1996,
            "title": "Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus type 4",
            "volume": "220"
        },
        "bib0115": {
            "authors": [
                {
                    "first": null,
                    "initial": null,
                    "last": "Toyohiro Urakawa"
                },
                {
                    "first": "Timothy J.",
                    "initial": "T.J.",
                    "last": "French"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": "Yuchi Adachi"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": "Akio Fukusho"
                },
                {
                    "first": "Helene",
                    "initial": "H.",
                    "last": "LeBlois"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Flamand"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Mertens"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Roy"
                }
            ],
            "doi": "10.1016/0168-1702(94)90001-9",
            "firstpage": "149",
            "issn": "01681702",
            "lastpage": "161",
            "pmid": "8178571",
            "pub_year": 1994,
            "title": "Synthesis of recombinant baculoviruses expressing the outer capsid protein VP2 of five BTV serotypes and the induction of neutralizing antibodies to homologous and heterologous BTV serotypes",
            "volume": "31"
        },
        "bib0120": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Du Plessis"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Cloete"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Aitchison"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Van Dijk"
                }
            ],
            "firstpage": "321",
            "issn": "00302465",
            "lastpage": "329",
            "pmid": "10192846",
            "pub_year": 1998,
            "title": "Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines",
            "volume": "65"
        },
        "bib0125": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Boyce"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Roy"
                }
            ],
            "doi": "10.1128/JVI.01819-06",
            "firstpage": "2179",
            "issn": "0022538X",
            "lastpage": "2186",
            "pmid": "17151117",
            "pub_year": 2007,
            "title": "Recovery of infectious bluetongue virus from RNA",
            "volume": "81"
        },
        "bib0130": {
            "authors": [
                {
                    "first": "Sushila",
                    "initial": "S.",
                    "last": "Maan"
                },
                {
                    "first": "Shujing",
                    "initial": "S.",
                    "last": "Rao"
                },
                {
                    "first": "Narender Singh",
                    "initial": "N.S.",
                    "last": "Maan"
                },
                {
                    "first": "Simon John",
                    "initial": "S.J.",
                    "last": "Anthony"
                },
                {
                    "first": "Houssam",
                    "initial": "H.",
                    "last": "Attoui"
                },
                {
                    "first": "Alan Richard",
                    "initial": "A.R.",
                    "last": "Samuel"
                },
                {
                    "first": "Peter Paul Clement",
                    "initial": "P.P.C.",
                    "last": "Mertens"
                }
            ],
            "doi": "10.1016/j.jviromet.2007.02.016",
            "firstpage": "132",
            "issn": "01660934",
            "lastpage": "139",
            "pmid": "17433453",
            "pub_year": 2007,
            "title": "Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses",
            "volume": "143"
        },
        "bib0135": {
            "authors": [
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Matsuura"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Possee"
                },
                {
                    "first": "H. A.",
                    "initial": "H.A.",
                    "last": "Overton"
                },
                {
                    "first": "D. H.L.",
                    "initial": "D.H.L.",
                    "last": "Bishop"
                }
            ],
            "doi": "10.1099/0022-1317-68-5-1233",
            "firstpage": "1233",
            "issn": "00221317",
            "lastpage": "1250",
            "pmid": "3553425",
            "pub_year": 1987,
            "title": "Baculovirus expression vectors: The requirements for high level expression of proteins, including glycoproteins",
            "volume": "68"
        },
        "bib0140": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Wensvoort"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Terpstra"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Boonstra"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Bloemraad"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Van Zaane"
                }
            ],
            "doi": "10.1016/0378-1135(86)90072-6",
            "firstpage": "101",
            "issn": "03781135",
            "lastpage": "108",
            "pmid": "2428160",
            "pub_year": 1986,
            "title": "Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis",
            "volume": "12"
        },
        "bib0145": {
            "authors": [
                {
                    "first": "Yuta",
                    "initial": "Y.",
                    "last": "Kanai"
                },
                {
                    "first": "T. N.",
                    "initial": "T.N.",
                    "last": "Athmaram"
                },
                {
                    "first": "Meredith",
                    "initial": "M.",
                    "last": "Stewart"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Roy"
                }
            ],
            "doi": "10.1016/j.pep.2013.07.005",
            "firstpage": "77",
            "issn": "10465928",
            "lastpage": "84",
            "pmid": "23872366",
            "pub_year": 2013,
            "title": "Multiple large foreign protein expression by a single recombinant baculovirus: A system for production of multivalent vaccines",
            "volume": "91"
        },
        "bib0150": null,
        "bib0155": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Stewart"
                },
                {
                    "first": "C. I.",
                    "initial": "C.I.",
                    "last": "Dovas"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Chatzinasiou"
                },
                {
                    "first": "T. N.",
                    "initial": "T.N.",
                    "last": "Athmaram"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Papanastassopoulou"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Papadopoulos"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Roy"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.01.042",
            "firstpage": "2131",
            "issn": "0264410X",
            "lastpage": "2139",
            "pmid": "22285887",
            "pub_year": 2012,
            "title": "Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: Presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection",
            "volume": "30"
        },
        "bib0160": null,
        "bib0165": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Capocefalo"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Franceschi"
                },
                {
                    "first": "P. P.",
                    "initial": "P.P.",
                    "last": "Mertens"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Castillo-Olivares"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Cavirani"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Di Lonardo"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Leni"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Donofrio"
                }
            ],
            "doi": "10.1016/j.jviromet.2010.08.002",
            "firstpage": "420",
            "issn": "01660934",
            "lastpage": "424",
            "pmid": "20705105",
            "pub_year": 2010,
            "title": "Expression and secretion of Bluetongue virus serotype 8 (BTV-8)VP2 outer capsid protein by mammalian cells",
            "volume": "169"
        },
        "bib0170": {
            "authors": [
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Mart\u00ednez-Torrecuadrada"
                },
                {
                    "first": "J. P.M.",
                    "initial": "J.P.M.",
                    "last": "Langeveld"
                },
                {
                    "first": "R. H.",
                    "initial": "R.H.",
                    "last": "Meloen"
                },
                {
                    "first": "J. I.",
                    "initial": "J.I.",
                    "last": "Casal"
                }
            ],
            "doi": "10.1099/0022-1317-82-10-2415",
            "firstpage": "2415",
            "issn": "00221317",
            "lastpage": "2424",
            "pmid": "11562535",
            "pub_year": 2001,
            "title": "Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides",
            "volume": "82"
        },
        "bib0175": {
            "authors": [
                {
                    "first": "A. C.",
                    "initial": "A.C.",
                    "last": "Potgieter"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Cloete"
                },
                {
                    "first": "P. J.",
                    "initial": "P.J.",
                    "last": "Pretorius"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "van Dijk"
                }
            ],
            "doi": "10.1099/vir.0.18919-0",
            "firstpage": "1317",
            "issn": "00221317",
            "lastpage": "1326",
            "pmid": "12692299",
            "pub_year": 2003,
            "title": "A first full outer capsid protein sequence data-set in the Orbivirus genus (family Reoviridae): Cloning, sequencing, expression and analysis of a complete set of full-length outer capsid VP2 genes of the nine African horsesickness virus serotypes",
            "volume": "84"
        },
        "bib0180": {
            "authors": [
                {
                    "first": "Beate F.",
                    "initial": "B.F.",
                    "last": "von Teichman"
                },
                {
                    "first": "Theresa K.",
                    "initial": "T.K.",
                    "last": "Smit"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.07.037",
            "firstpage": "5014",
            "issn": "0264410X",
            "lastpage": "5021",
            "pmid": "18682269",
            "pub_year": 2008,
            "title": "Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals",
            "volume": "26"
        },
        "bib0185": {
            "authors": [
                {
                    "first": "Beate F.",
                    "initial": "B.F.",
                    "last": "von Teichman"
                },
                {
                    "first": "Baptiste",
                    "initial": "B.",
                    "last": "Dungu"
                },
                {
                    "first": "Theresa K.",
                    "initial": "T.K.",
                    "last": "Smit"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.06.105",
            "firstpage": "6505",
            "issn": "0264410X",
            "lastpage": "6517",
            "pmid": "20638456",
            "pub_year": 2010,
            "title": "In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6",
            "volume": "28"
        }
    },
    "body_text": [
        {
            "endOffset": 23448,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Non-neutralizing Abs still could cross-react between serotypes by binding to common epitopes.",
            "startOffset": 23355,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 15176,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The virus titer was measured by standard plaque assay using Sf21 cells.",
            "startOffset": 15105,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 17576,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "At day 21, all guinea pigs were boosted by the same procedure and with the same amount of proteins.",
            "startOffset": 17477,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 25108,
            "parents": [],
            "secId": "sec0070",
            "sentence": "This is the first report to show that VP2 of all nine AHSV serotypes induce serotype specific nAbs with slight cross-neutralizing antibodies.",
            "startOffset": 24967,
            "title": "Discussion"
        },
        {
            "endOffset": 12630,
            "parents": [],
            "refoffsets": {
                "bib0100": {
                    "endOffset": 12629,
                    "startOffset": 12622
                },
                "bib0105": {
                    "endOffset": 12629,
                    "startOffset": 12622
                },
                "bib0110": {
                    "endOffset": 12629,
                    "startOffset": 12622
                },
                "bib0115": {
                    "endOffset": 12629,
                    "startOffset": 12622
                }
            },
            "secId": "sec0005",
            "sentence": "Outer capsid protein VP2 of orbiviruses determines the serotype and is the main target of nAbs [20\u201323].",
            "startOffset": 12527,
            "title": "Introduction"
        },
        {
            "endOffset": 17193,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Shortly before immunization, recombinant VP2 proteins or PBS in 1.5 ml were warmed to 37 \u00b0C and mixed with an equal volume of Montanide 206VG (Seppic) by vortexing.",
            "startOffset": 17029,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 25302,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Further, some VP2 genes were optimized to increase protein expression.",
            "startOffset": 25232,
            "title": "Discussion"
        },
        {
            "endOffset": 29483,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Thus, formulation of VP2 cocktails to protect horses against all included serotypes is also complicated by differences in immunogenicity and possible interference between VP2 proteins to induce humoral immune responses.",
            "startOffset": 29264,
            "title": "Discussion"
        },
        {
            "endOffset": 29982,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Further, nAb titers against each VP2 protein differed strongly after immunization with a cocktail or with single VP2 protein.",
            "startOffset": 29857,
            "title": "Discussion"
        },
        {
            "endOffset": 26053,
            "parents": [],
            "secId": "sec0070",
            "sentence": "In this study, guinea pigs were immunized with insect cell lysate containing 50 \u03bcg of VP2 to elicit detectable antibodies.",
            "startOffset": 25931,
            "title": "Discussion"
        },
        {
            "endOffset": 30908,
            "parents": [],
            "refoffsets": {
                "bib0185": {
                    "endOffset": 30907,
                    "startOffset": 30903
                }
            },
            "secId": "sec0070",
            "sentence": "However, when using cocktails of LAVs it was also suggested that there are substantial differences in cross-reactivity between serotypes; e.g. cross-reactivity between AHSV-5 and -8 seems to be stronger than between AHSV-6 and -9 [37].",
            "startOffset": 30673,
            "title": "Discussion"
        },
        {
            "endOffset": 28194,
            "parents": [],
            "secId": "sec0070",
            "sentence": "This phenomenon is probably due to the structural similarity and dissimilarity between VP2s of relevant serotypes.",
            "startOffset": 28080,
            "title": "Discussion"
        },
        {
            "endOffset": 19537,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0140": {
                    "endOffset": 19536,
                    "startOffset": 19532
                }
            },
            "secId": "sec0040",
            "sentence": "Monolayers were stained by IPMA with sera diluted 1:500, followed by incubation with conjugated \u03b1-guinea pig rabbit serum (DAKO) and stained according to standard procedures [28].",
            "startOffset": 19358,
            "title": "Immunostaining of AHSV-infected monolayers"
        },
        {
            "endOffset": 23544,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Therefore, serotype specificity was further studied by immunoperoxydase monolayer assay (IPMA).",
            "startOffset": 23449,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 14470,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "For AHSV serotypes 1, 3, 7, 8 and 9, open reading frames based on amino acid sequences of VP2 proteins (GenBank accession number: CAP04841; U01832; AAN74570; ABI96883, respectively), were designed for optimized expression in insect cells (Gene Art, Regensburg, Germany).",
            "startOffset": 14200,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 10820,
            "parents": [],
            "refoffsets": {
                "bib0005": {
                    "endOffset": 10819,
                    "startOffset": 10814
                },
                "bib0015": {
                    "endOffset": 10819,
                    "startOffset": 10814
                }
            },
            "secId": "sec0005",
            "sentence": "In 1987, an outbreak of AHSV-4 on the Iberian Peninsula, which was extended for a few years in Spain and spread to Portugal and Morocco indicating that AHSV had overwintered and spread by European Culicoides midges [1,3].",
            "startOffset": 10599,
            "title": "Introduction"
        },
        {
            "endOffset": 15104,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "After the first passage, supernatants were transferred to fresh Sf9 cells every 3\u20135 days until virus infection was confirmed by light microscopy.",
            "startOffset": 14959,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 15610,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Cell pellets were suspended in 25 mM sodium bicarbonate (NaHCO3, pH 8.39) at 1.0 \u00d7 107 cells/ml.",
            "startOffset": 15514,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 19982,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Recombinant VP2 proteins of nine AHSV serotypes were expressed in Sf9 cells using the baculovirus expression system with VP2 genes under the control of the polyhedron promoter.",
            "startOffset": 19806,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 19357,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0040",
            "sentence": "At the beginning of cytopathic effect (CPE), medium was removed and monolayers were washed with PBS, and fixed with methanol/acetone (1:1) according to standard procedures.",
            "startOffset": 19185,
            "title": "Immunostaining of AHSV-infected monolayers"
        },
        {
            "endOffset": 13950,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Insect cell lines of Spodoptera frugiperda, Sf9 and Sf21, were cultured at 28 \u00b0C in Insect-Xpress (Lonza, Basel, Switzerland) and TC100 medium (Biochrom AG, Berlin, Germany), respectively.",
            "startOffset": 13762,
            "title": "Viruses and cells"
        },
        {
            "endOffset": 17846,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0105": {
                    "endOffset": 17845,
                    "startOffset": 17841
                }
            },
            "secId": "sec0035",
            "sentence": "Guinea pig sera collected at the end of the experiment, day 42, were examined for nAbs by plaque reduction based standard neutralizing assay [21].",
            "startOffset": 17700,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 20946,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Guinea pigs were immunized twice with 50 \u03bcg of VP2 protein after mixing with an equal volume of Montanide 206VG according to a prime-boost protocol with an interval of 3 weeks.",
            "startOffset": 20770,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 26400,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Further, cross-neutralization antibodies between genetically related serotypes were detected, but most of those cross-neutralizing Abs titers were considerably lower than for the respective serotype.",
            "startOffset": 26201,
            "title": "Discussion"
        },
        {
            "endOffset": 11578,
            "parents": [],
            "refoffsets": {
                "bib0020": {
                    "endOffset": 11577,
                    "startOffset": 11572
                },
                "bib0025": {
                    "endOffset": 11577,
                    "startOffset": 11572
                },
                "bib0030": {
                    "endOffset": 11577,
                    "startOffset": 11572
                },
                "bib0035": {
                    "endOffset": 11577,
                    "startOffset": 11572
                },
                "bib0040": {
                    "endOffset": 11577,
                    "startOffset": 11572
                },
                "bib0045": {
                    "endOffset": 11577,
                    "startOffset": 11572
                }
            },
            "secId": "sec0005",
            "sentence": "Dominant antigenic sites inducing serotype specific neutralizing antibodies (nAbs) are mainly located on VP2, however, other structural and non-structural proteins \u2013 VP3, VP5, VP7, NS1 and NS2 \u2013 also induce humoral and cellular immune responses [4\u20139].",
            "startOffset": 11327,
            "title": "Introduction"
        },
        {
            "endOffset": 23833,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "As expected, guinea pig sera raised against single VP2 proteins immunostained monolayers infected with the homologous AHSV serotype (Table 2).",
            "startOffset": 23691,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 26463,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Moreover, some expected cross-reactive nAbs were not detected.",
            "startOffset": 26401,
            "title": "Discussion"
        },
        {
            "endOffset": 15513,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Infected cells were incubated at 28 \u00b0C for 72 h. Then, infected cells were harvested by centrifugation, washed with phosphate buffered saline (PBS) and pelleted by centrifugation.",
            "startOffset": 15334,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 17352,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Each animal received 400 \u03bcl containing adjuvanted 50 \u03bcg of VP2 protein by subcutaneous injection of 100 \u03bcl at four places left and right from the spinal cord.",
            "startOffset": 17194,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 30508,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Currently used cocktails of live-attenuated vaccines (LAVs) induce a broader protection.",
            "startOffset": 30420,
            "title": "Discussion"
        },
        {
            "endOffset": 14613,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0135": {
                    "endOffset": 14612,
                    "startOffset": 14608
                }
            },
            "secId": "sec0020",
            "sentence": "VP2 genes were amplified by PCR with specific primers containing BamHI or SmaI site for cloning purposes into the transfer vector pAcYM1 [27].",
            "startOffset": 14471,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 26715,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Unfortunately challenge experiments could not be performed in guinea pigs, as horses are the natural host for AHSV.",
            "startOffset": 26600,
            "title": "Discussion"
        },
        {
            "endOffset": 11326,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The virus particle consists of three distinct protein layers, of which the VP2 and VP5 proteins form the outer shell and are the most variable proteins of AHSV.",
            "startOffset": 11166,
            "title": "Introduction"
        },
        {
            "endOffset": 12336,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Currently, LAVs are not licensed in Europe.",
            "startOffset": 12293,
            "title": "Introduction"
        },
        {
            "endOffset": 13761,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0125": {
                    "endOffset": 13760,
                    "startOffset": 13756
                }
            },
            "secId": "sec0015",
            "sentence": "Virus titers were determined by a plaque-forming assay in BSR cells and defined as plaque forming units per ml (pfu/ml) as described [25].",
            "startOffset": 13623,
            "title": "Viruses and cells"
        },
        {
            "endOffset": 12292,
            "parents": [],
            "refoffsets": {
                "bib0050": {
                    "endOffset": 12291,
                    "startOffset": 12287
                }
            },
            "secId": "sec0005",
            "sentence": "Moreover, the recent outbreak of AHSV serotype 9 in Gambia is suspected to be derived from vaccine strains [10].",
            "startOffset": 12180,
            "title": "Introduction"
        },
        {
            "endOffset": 25930,
            "parents": [],
            "refoffsets": {
                "bib0070": {
                    "endOffset": 25929,
                    "startOffset": 25925
                },
                "bib0105": {
                    "endOffset": 25813,
                    "startOffset": 25809
                }
            },
            "secId": "sec0070",
            "sentence": "Previously, purified AHSV VP2 seemed to be less immunogenic in rabbits [21], but as little as 5 \u03bcg of VP2 protein in insect cell lysate could protect horses from AHS by induction of nAbs [14].",
            "startOffset": 25738,
            "title": "Discussion"
        },
        {
            "endOffset": 16717,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Adult female guinea pigs were purchased from a registered breeding farm for guinea pigs and were randomly divided into groups of six animals.",
            "startOffset": 16576,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 31659,
            "parents": [],
            "secId": "sec0070",
            "sentence": "DIVA testing by these commercially available tests will be very supportive in combination with vaccination with VP2 subunit vaccine.",
            "startOffset": 31527,
            "title": "Discussion"
        },
        {
            "endOffset": 14009,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "TC100 medium was supplemented with 10% fetal bovine serum.",
            "startOffset": 13951,
            "title": "Viruses and cells"
        },
        {
            "endOffset": 23354,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Titers of nAbs raised against different VP2 proteins demonstrated a high level of serotype specificity.",
            "startOffset": 23251,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 22146,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "It is possible that this is due to the 4\u20135 times lower dose per VP2 protein in the cocktails compared to the single VP2 immunization; i.e. 50 \u03bcg of VP2 proteins were inoculated for single VP2 vaccination, whereas 10 \u03bcg per VP2 in the pentavalent cocktail and 12.5 \u03bcg per VP2 in the quadrivalent cocktail was injected.",
            "startOffset": 21829,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 24112,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "In contrast to the cross-neutralization results (Table 1), AHSV-6 was not recognized by \u03b1-AHSV-9 VP2 serum (Table 2).",
            "startOffset": 23995,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 11061,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The virus particle contains ten genome segments of double-stranded RNA (dsRNA) encoding seven structural proteins (VP1-VP7).",
            "startOffset": 10937,
            "title": "Introduction"
        },
        {
            "endOffset": 18118,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "As a control, each virus was mixed with an equal volume of DMEM without any serum.",
            "startOffset": 18036,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 24655,
            "parents": [],
            "refoffsets": {
                "bib0085": {
                    "endOffset": 24654,
                    "startOffset": 24641
                },
                "bib0105": {
                    "endOffset": 24654,
                    "startOffset": 24641
                },
                "bib0110": {
                    "endOffset": 24654,
                    "startOffset": 24641
                },
                "bib0115": {
                    "endOffset": 24654,
                    "startOffset": 24641
                },
                "bib0155": {
                    "endOffset": 24654,
                    "startOffset": 24641
                }
            },
            "secId": "sec0070",
            "sentence": "VP2 protein of orbiviruses is the major determinant of eliciting nAbs and has been used as recombinant protein-based vaccine in previous studies [17,21\u201323,31].",
            "startOffset": 24496,
            "title": "Discussion"
        },
        {
            "endOffset": 26200,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Each VP2 elicited serotype specific Abs, but nAb titers varied considerably among different AHSV serotypes, from 37 for AHSV-2 to 1365 for AHSV-6.",
            "startOffset": 26054,
            "title": "Discussion"
        },
        {
            "endOffset": 32439,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The considerable difference in immunogenicity between VP2 proteins in guinea pigs has to be taken into account and should be investigated further prior to the formulation of single as well as cocktail VP2 subunit vaccines for African horse sickness.",
            "startOffset": 32190,
            "title": "Discussion"
        },
        {
            "endOffset": 24818,
            "parents": [],
            "refoffsets": {
                "bib0160": {
                    "endOffset": 24817,
                    "startOffset": 24813
                }
            },
            "secId": "sec0070",
            "sentence": "Particularly, VP2 of AHSV serotype 4 has been studied extensively by European research groups, as the last European AHS outbreak was caused by this serotype [32].",
            "startOffset": 24656,
            "title": "Discussion"
        },
        {
            "endOffset": 30672,
            "parents": [],
            "refoffsets": {
                "bib0180": {
                    "endOffset": 30671,
                    "startOffset": 30667
                }
            },
            "secId": "sec0070",
            "sentence": "Even LAV for serotype 5 and 9 are not included, and protection against AHSV-5 and -9 are achieved by serotype-related LAVs for serotype 8 and 6, respectively [36].",
            "startOffset": 30509,
            "title": "Discussion"
        },
        {
            "endOffset": 21358,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Despite the same amount of recombinant VP2 proteins being used in each group and in each guinea pig, serotype specific nAb titers strongly varied between groups, and also between animals within the same group.",
            "startOffset": 21149,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 23690,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Pooled sera per group were 500-fold diluted and used in IPMA to immunostain BSR monolayers infected with each of the nine reference AHSV strains.",
            "startOffset": 23545,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 29636,
            "parents": [],
            "refoffsets": {
                "bib0175": {
                    "endOffset": 29635,
                    "startOffset": 29631
                }
            },
            "secId": "sec0070",
            "sentence": "We intended to induce humoral responses against closely related and possibly more serotypes than included in the cocktail by a prime-boost approach [35].",
            "startOffset": 29483,
            "title": "Discussion"
        },
        {
            "endOffset": 27377,
            "parents": [],
            "secId": "sec0070",
            "sentence": "It would be thought that more antibodies to non-neutralizing than to neutralizing domains of AHSV-5 and AHSV-8 VP2 were elicited.",
            "startOffset": 27248,
            "title": "Discussion"
        },
        {
            "endOffset": 28607,
            "parents": [],
            "secId": "sec0070",
            "sentence": "However, this reduction was not linearly related to the amount of injected VP2.",
            "startOffset": 28528,
            "title": "Discussion"
        },
        {
            "endOffset": 31367,
            "parents": [],
            "secId": "sec0070",
            "sentence": "In contrast, VP2 subunit vaccine induces Abs solely against VP2, and horses vaccinated with VP2 subunit vaccines should therefore be seronegative for VP7 antibodies.",
            "startOffset": 31202,
            "title": "Discussion"
        },
        {
            "endOffset": 27539,
            "parents": [],
            "secId": "sec0070",
            "sentence": "These variations in the feasibility of eliciting non-neutralizing Abs and nAbs between serotypes could contribute the considerable differences in the nAb titers.",
            "startOffset": 27378,
            "title": "Discussion"
        },
        {
            "endOffset": 28264,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Here, we have also studied two cocktails of four or five VP2 proteins.",
            "startOffset": 28194,
            "title": "Discussion"
        },
        {
            "endOffset": 28891,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The reduction of 4\u20135 fold VP2 protein in cocktails resulted in 4 to 40 fold reduced nAb titers compared to single VP2 immunization; e.g. for serotype 5, 179 by single and 53 by cocktail VP2 (\u00b130% difference), and for serotype 9, 853 by single and 19 by cocktail VP2 (\u00b12% difference).",
            "startOffset": 28608,
            "title": "Discussion"
        },
        {
            "endOffset": 10310,
            "parents": [],
            "refoffsets": {
                "bib0005": {
                    "endOffset": 10309,
                    "startOffset": 10304
                },
                "bib0010": {
                    "endOffset": 10309,
                    "startOffset": 10304
                }
            },
            "secId": "sec0005",
            "sentence": "These equids are carriers of AHSV, which is transmitted by Culicoides midges, in particular by C. imicola in endemic areas [1,2].",
            "startOffset": 10181,
            "title": "Introduction"
        },
        {
            "endOffset": 31201,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Furthermore, LAVs induce an immune response against all viral proteins and are therefore not \u2018DIVA\u2019 (differentiating infected from vaccinated animals) vaccines.",
            "startOffset": 31041,
            "title": "Discussion"
        },
        {
            "endOffset": 18035,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "Briefly, serially 2-fold diluted sera in DMEM were mixed with an equal volume of each AHSV reference strain virus (20\u201340 pfu/25 \u03bcl) and incubated at 37 \u00b0C for 60 min in a 5% CO2 incubator.",
            "startOffset": 17847,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 23994,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "Similar to cross-neutralization of genetically related AHSV serotypes, some monolayers infected with genetically related AHSV serotypes were also immunostained.",
            "startOffset": 23834,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 26802,
            "parents": [],
            "refoffsets": {
                "bib0085": {
                    "endOffset": 26801,
                    "startOffset": 26797
                }
            },
            "secId": "sec0070",
            "sentence": "The AHSV infection model using interferon-\u03b1 knockout mice were recently reported [17].",
            "startOffset": 26716,
            "title": "Discussion"
        },
        {
            "endOffset": 11699,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Since there is no successful treatment for AHS, vaccination is the most important approach to protect horses against AHS.",
            "startOffset": 11578,
            "title": "Introduction"
        },
        {
            "endOffset": 11850,
            "parents": [],
            "refoffsets": {
                "bib0005": {
                    "endOffset": 11849,
                    "startOffset": 11846
                }
            },
            "secId": "sec0005",
            "sentence": "Live-attenuated vaccines (LAVs) obtained by serial passages of AHSV in cell culture are available commercially for most serotypes in South Africa [1].",
            "startOffset": 11700,
            "title": "Introduction"
        },
        {
            "endOffset": 10598,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Currently, AHSV is endemic in tropical and sub-Saharan Africa, but sporadic cases and short-term epidemics in North Africa and Middle-East have been reported in the mid-20th century.",
            "startOffset": 10416,
            "title": "Introduction"
        },
        {
            "endOffset": 10936,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The serogroup AHSV within the genus Orbivirus of the Reoviridae family consists of nine serotypes (AHSV-1 \u2013 AHSV-9).",
            "startOffset": 10820,
            "title": "Introduction"
        },
        {
            "endOffset": 18393,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "After absorption of virus for 1 h at 37 \u00b0C, cells were overlaid with DMEM- 1% low-melting agarose gel, followed by incubation at 37 \u00b0C for 2\u20134 days until plaques were visible.",
            "startOffset": 18218,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 20553,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "After centrifugation, the clarified supernatant was used for immunization of guinea pigs.",
            "startOffset": 20464,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 24485,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "In general this immunostaining was weaker than for the respective homologous AHSV serotype (Table 2).",
            "startOffset": 24384,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 28079,
            "parents": [],
            "secId": "sec0070",
            "sentence": "In contrast to AHSV-5 and -8, VP2 of AHSV serotype 9 induced nAbs against serotype 6 (nAb titer of 12 with 95% CI: 3\u201321) which was not detectable by IPMA, suggesting that the non-nAb is not necessarily higher than nAb.",
            "startOffset": 27861,
            "title": "Discussion"
        },
        {
            "endOffset": 24383,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "AHSV-5 was also recognized by \u03b1-VP2 of AHSV-3.",
            "startOffset": 24337,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 25389,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Still, quantities of soluble VP2 significantly varied between the different serotypes.",
            "startOffset": 25303,
            "title": "Discussion"
        },
        {
            "endOffset": 13340,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The results demonstrated that recombinant VP2 proteins of all nine AHSV serotypes have the potential to be used as safe subunit vaccines for AHS either individually or in a multi-serotype cocktail.",
            "startOffset": 13143,
            "title": "Introduction"
        },
        {
            "endOffset": 19025,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0040",
            "sentence": "Pooled sera collected prior to immunization (day 0) were used as negative control serum.",
            "startOffset": 18937,
            "title": "Immunostaining of AHSV-infected monolayers"
        },
        {
            "endOffset": 32189,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The guinea pig model can be initially used for immunogenicity studies in order to reduce experiments in horses.",
            "startOffset": 32078,
            "title": "Discussion"
        },
        {
            "endOffset": 31898,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Thus, rapid control of AHS outbreaks as well as confirming the virus-free status of animals for international movements irrespective of the vaccination status can be achieved with the current available and extensively validated VP7 ELISA.",
            "startOffset": 31660,
            "title": "Discussion"
        },
        {
            "endOffset": 22357,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "The lower nAb titer by cocktails compared to single VP2 protein varied from 3 to 4 times lower for serotype 5 to \u223c45 times lower for serotype 9 after immunization with these VP2 proteins in cocktails (Table 1).",
            "startOffset": 22147,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 23169,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Immunization with VP2 cocktails did not result in significant nAbs titers against genetically unrelated serotypes, and only a very low nAb titer against a related serotype (\u03b1-AHSV-5 VP2 serum for serotype 8) could be detected (Table 1).",
            "startOffset": 22933,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 15971,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "To examine the amount of VP2 proteins, soluble VP2 were mixed with equal volumes of SDS-PAGE sample buffer (10 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 2% \u03b2-mercaptoethanol, 20% glycerol, 0.05% bromophenol blue).",
            "startOffset": 15765,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 18626,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "The neutralizing tests were performed in duplicate.",
            "startOffset": 18575,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 29795,
            "parents": [],
            "secId": "sec0070",
            "sentence": "However, genetically related VP2 proteins 3 and 7, or 5 and 8, (Fig. 2) in each of the cocktails did not increase nAbs titers against their related serotypes.",
            "startOffset": 29637,
            "title": "Discussion"
        },
        {
            "endOffset": 20717,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Concentrations of VP2 protein were estimated at 100 \u03bcg/ml by comparing with bovine serum albumin (BSA) standard on a Coomassie Brilliant Blue stained SDS-PAGE gel.",
            "startOffset": 20554,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 20259,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib0145": {
                    "endOffset": 20258,
                    "startOffset": 20254
                }
            },
            "secId": "sec0055",
            "sentence": "The differences in VP2 expression were less obvious in Sf21 cells as shown in our previous study [29].",
            "startOffset": 20157,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 24966,
            "parents": [],
            "secId": "sec0070",
            "sentence": "In this report we studied the immunogenicity of VP2 proteins of all nine AHSV serotypes as a first step in the development of AHS subunit vaccines.",
            "startOffset": 24819,
            "title": "Discussion"
        },
        {
            "endOffset": 11165,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Additionally, at least three non-structural proteins (NS1-NS3) are synthesized in virus infected cells.",
            "startOffset": 11062,
            "title": "Introduction"
        },
        {
            "endOffset": 12913,
            "parents": [],
            "secId": "sec0005",
            "sentence": "To date, there are no reports regarding the immunogenicity of VP2 proteins of other serotypes of AHSV.",
            "startOffset": 12811,
            "title": "Introduction"
        },
        {
            "endOffset": 20463,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Recombinant baculovirus-infected cells were collected by centrifugation and lysed by homogenization in 25 mM sodium bicarbonate.",
            "startOffset": 20335,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 25587,
            "parents": [],
            "refoffsets": {
                "bib0165": {
                    "endOffset": 25586,
                    "startOffset": 25582
                }
            },
            "secId": "sec0070",
            "sentence": "Since it is generally known that recombinant VP2 protein of orbivirus is highly insoluble, it is likely that quantities of soluble VP2 proteins vary by differences in expression or solubility [33].",
            "startOffset": 25390,
            "title": "Discussion"
        },
        {
            "endOffset": 22698,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "For example, \u03b1-AHSV-3 VP2 serum for serotype 7, \u03b1-AHSV-5 VP2 serum for serotype 8, and \u03b1-AHSV-6 and \u03b1-AHSV-9 VP2 serum both showed nAbs titers for the genetically related serotype: i.e. serotype 9, and 6, respectively (Table 1).",
            "startOffset": 22470,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 12019,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Although LAVs have been extensively used in South Africa and other African countries, there are still concerns as LAVs cause viremia and could be transmitted by midges.",
            "startOffset": 11851,
            "title": "Introduction"
        },
        {
            "endOffset": 14844,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Recombinant vectors pAcYM1 with VP2 genes were purified and co-transfected into Sf9 cells with linearized baculovirus DNA (strain BAC10:KO1629), using Cellfectin\u00ae II Reagent (Invitrogen) according to the manufacturer's instruction.",
            "startOffset": 14613,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 12179,
            "parents": [],
            "secId": "sec0005",
            "sentence": "However, the biggest concern of using these vaccines is reassortment between LAVs or with wild type AHSV, which could result in more pathogenic virus variants.",
            "startOffset": 12020,
            "title": "Introduction"
        },
        {
            "endOffset": 30291,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Perhaps, AHSV serotypes have common epitopes on VP2 but these differ in avidity or affinity for these Abs.",
            "startOffset": 30185,
            "title": "Discussion"
        },
        {
            "endOffset": 13622,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "AHSV reference strains (obtained from ANSES, France) were passaged and amplified in BSR cells, a derivative of the BHK-21 cell line, in Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with 10% fetal bovine serum (Invitrogen).",
            "startOffset": 13382,
            "title": "Viruses and cells"
        },
        {
            "endOffset": 29263,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The lower serotype specific nAb titer after immunization with cocktails of VP2 proteins could also be due to the simultaneous presentation of various serotype specific epitopes to the immune system or due to the immunodominance of certain serotype specific epitopes.",
            "startOffset": 28997,
            "title": "Discussion"
        },
        {
            "endOffset": 18217,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "After incubation, 50 \u03bcl neutralized viruses were used to infect BSR monolayers in a 12-well plate.",
            "startOffset": 18119,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 27712,
            "parents": [],
            "refoffsets": {
                "bib0170": {
                    "endOffset": 27711,
                    "startOffset": 27707
                }
            },
            "secId": "sec0070",
            "sentence": "Although the crystal structure of AHSV VP2 has not been solved, neutralizing domains on the secondary structure containing amino acid 199\u2013689 of VP2 were demonstrated [34].",
            "startOffset": 27540,
            "title": "Discussion"
        },
        {
            "endOffset": 18936,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0040",
            "sentence": "Equal volumes of sera from guinea pigs of each group collected at the end of the experiment were pooled and examined for AHSV specific antibodies (Abs) by immunoperoxydase monolayer assay (IPMA).",
            "startOffset": 18741,
            "title": "Immunostaining of AHSV-infected monolayers"
        },
        {
            "endOffset": 13142,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In this report, VP2 of all nine AHSV serotypes were produced individually using the baculovirus expression system and their immunogenic activities were investigated by immunization of guinea pigs, singly or in cocktail mixtures.",
            "startOffset": 12914,
            "title": "Introduction"
        },
        {
            "endOffset": 21067,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "At day 42 of the experiment, sera were collected and tested for the neutralization activities as described in Section 2.",
            "startOffset": 20947,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 15764,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Cells were disrupted by dounce homogenization and after centrifugation at 6000 rpm for 3 min, supernatants containing soluble VP2 protein were collected.",
            "startOffset": 15611,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 20156,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Higher expression of VP2 was obtained with codon optimized VP2 genes for serotypes 1, 3, 7, 8 and 9 than with the original VP2 sequences for serotype 2, 4, 5 and 6 (Fig. 1).",
            "startOffset": 19983,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 25737,
            "parents": [],
            "secId": "sec0070",
            "sentence": "VP2 proteins of each AHSV serotype were produced in insect cells and each induced detectable nAb titers in guinea pigs as an alternative animal model.",
            "startOffset": 25587,
            "title": "Discussion"
        },
        {
            "endOffset": 31526,
            "parents": [],
            "secId": "sec0070",
            "sentence": "An AHSV infection results rapidly in seroconversion for VP7 antibody and VP7 is the target for several commercially available tests to detect AHSV infections.",
            "startOffset": 31368,
            "title": "Discussion"
        },
        {
            "endOffset": 19746,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0045",
            "sentence": "Phylogenetic trees of the AHSV VP2 deduced amino acid sequences were constructed using 39 sequences of AHSV VP2 obtained from GenBank by the neighbor-joining method using MEGA 4.1 software.",
            "startOffset": 19557,
            "title": "Phylogenetic tree"
        },
        {
            "endOffset": 20334,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Soluble VP2 protein of each serotype was harvested at 72 h post-infection.",
            "startOffset": 20260,
            "title": "Expression of recombinant AHSV VP2 of 9 serotypes"
        },
        {
            "endOffset": 32077,
            "parents": [],
            "secId": "sec0070",
            "sentence": "In summary, we demonstrated that multi-serotype VP2 subunit vaccines for AHS are potentially feasible, as shown here by immunization of guinea pigs as an alternative animal model.",
            "startOffset": 31898,
            "title": "Discussion"
        },
        {
            "endOffset": 18696,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "The average and 95% confidence interval was calculated in each group.",
            "startOffset": 18627,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 18574,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "The neutralization titers were calculated by the reciprocal value of the maximum dilution, at which the number of plaques showed 50% reduction compared with the serum-free control.",
            "startOffset": 18394,
            "title": "Detection of neutralizing antibodies (nAbs)"
        },
        {
            "endOffset": 15333,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Recombinant baculoviruses expressing AHSV VP2 were used to infect Sf9 cells with a multiplicity of infection (moi) of 5.",
            "startOffset": 15213,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 16278,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Concentrations of all samples were adjusted to 100 \u03bcg of VP2 per ml by 25 mM sodium bicarbonate and stored at \u221280 \u00b0 C until use.",
            "startOffset": 16150,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 21496,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "For example, nAb titers ranged from 37 (95% confidence interval (CI): 27\u201348) for AHSV-2 to as high as 1365 (95% CI: 942\u20131788) for AHSV-6.",
            "startOffset": 21359,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 30184,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Non-neutralizing Abs were raised by cocktails of VP2 proteins; i.e. Abs against serotype 4, 5 and 9 by the cocktail of 1, 3, 7, 8, and Abs against serotype 8 by the cocktail of 2, 4, 5, 6, 9 (Table 2).",
            "startOffset": 29983,
            "title": "Discussion"
        },
        {
            "endOffset": 22932,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Further, no significant nAb titers against genetically unrelated serotypes were found.",
            "startOffset": 22846,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 28527,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The results suggested a dose-dependent immune response, since all serotype specific nAb titers were lower after immunization with cocktails of VP2 proteins (10/12.5 \u03bcg of each VP2 per animal) than those with individual VP2 immunization (50 \u03bcg of VP2 per animal).",
            "startOffset": 28265,
            "title": "Discussion"
        },
        {
            "endOffset": 19184,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0040",
            "sentence": "In brief, BSR monolayers were infected at low multiplicity of infection with each of the reference strains representing all nine AHSV serotypes, respectively.",
            "startOffset": 19026,
            "title": "Immunostaining of AHSV-infected monolayers"
        },
        {
            "endOffset": 30420,
            "parents": [],
            "secId": "sec0070",
            "sentence": "As a result, binding to epitopes occurs and will immunostain AHSV infected monolayers but this binding will not neutralize AHSV.",
            "startOffset": 30292,
            "title": "Discussion"
        },
        {
            "endOffset": 21148,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Immunization with a single VP2 protein induced serotype specific nAbs (Table 1).",
            "startOffset": 21068,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 10415,
            "parents": [],
            "secId": "sec0005",
            "sentence": "It is believed that the distribution of AHSV is associated with the presence of these competent vectors.",
            "startOffset": 10311,
            "title": "Introduction"
        },
        {
            "endOffset": 16575,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "All experiments with live animals were performed under the guidelines of the European Community (86/609) and were approved by the Committee on the Ethics of Animal Experiments of the Central Veterinary Institute (Permit numbers: 2011-042 and 2011-170).",
            "startOffset": 16323,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 10180,
            "parents": [],
            "secId": "sec0005",
            "sentence": "AHSV infections of zebras and donkeys are less severe and mostly cause mild clinical symptoms or an asymptomatic infection.",
            "startOffset": 10057,
            "title": "Introduction"
        },
        {
            "endOffset": 26599,
            "parents": [],
            "secId": "sec0070",
            "sentence": "This lack of expected cross-reactive nAbs are most likely due to low titer of cross-reactive nAbs compared with serotype specific nAbs.",
            "startOffset": 26464,
            "title": "Discussion"
        },
        {
            "endOffset": 22469,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bib0150": {
                    "endOffset": 22468,
                    "startOffset": 22464
                }
            },
            "secId": "sec0060",
            "sentence": "Importantly, some cross-neutralization was also detected for a few genetically related serotypes (Fig. 1) [30].",
            "startOffset": 22358,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 24336,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0065",
            "sentence": "In addition to immunostaining of genetically related AHSV serotypes, some unrelated AHSV reference strains were also recognized in IPMA; e.g. AHSV-8 was recognized not only by \u03b1-VP2 sera of AHSV-5 and -8 but also by AHSV-4.",
            "startOffset": 24113,
            "title": "Serotype specificity of guinea pig sera raised against recombinant VP2 proteins"
        },
        {
            "endOffset": 27163,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Cross-reactive Abs to genetically related AHSV serotypes were shown by IPMA with lower Ab titers than serotype specific reactions, except for AHSV-5 and AHSV-8, in which \u03b1-AHSV-5 VP2 serum reacted strongly to both AHSV-5 and AHSV-8, and vice versa.",
            "startOffset": 26915,
            "title": "Discussion"
        },
        {
            "endOffset": 17654,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "At day 42 of the experiment, animals were sacrificed and sera were collected.",
            "startOffset": 17577,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 17476,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Cocktails contained equal amounts of each VP2; 12.5 \u03bcg of each VP2 (1, 3, 7 and 8) or 10 \u03bcg of each VP2 (2, 4, 5, 6 and 9).",
            "startOffset": 17353,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 14958,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "On day six after transfection, 200 \u03bcl of the supernatants were transferred to fresh Sf9 cells in 12-wells plates.",
            "startOffset": 14845,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 10056,
            "parents": [],
            "refoffsets": {
                "bib0005": {
                    "endOffset": 10055,
                    "startOffset": 10052
                }
            },
            "secId": "sec0005",
            "sentence": "African horse sickness virus (AHSV) is the causative agent of African horse sickness (AHS) which is lethal for up to 90% of infected domestic horses [1].",
            "startOffset": 9903,
            "title": "Introduction"
        },
        {
            "endOffset": 21828,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "However, nAb titers against each of the AHSV serotypes were consistently lower than those after immunization with single VP2 proteins.",
            "startOffset": 21694,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 27247,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Interestingly, no cross neutralization Abs between AHSV-5 and AHSV-8 were detected.",
            "startOffset": 27164,
            "title": "Discussion"
        },
        {
            "endOffset": 29856,
            "parents": [],
            "secId": "sec0070",
            "sentence": "No nAbs were detected against unrelated serotypes (Table 1).",
            "startOffset": 29796,
            "title": "Discussion"
        },
        {
            "endOffset": 21693,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "Two groups of animals injected with the cocktails containing VP2 proteins of serotypes 1, 3, 7 and 8, and of 2, 4, 5, 6 and 9, respectively, had nAb titers to the included AHSV serotypes (Table 1).",
            "startOffset": 21496,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 26915,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The use of the small animal model for our future VP2 vaccine study should help to evaluate the vaccine efficacy.",
            "startOffset": 26803,
            "title": "Discussion"
        },
        {
            "endOffset": 25231,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The baculovirus expression system was used to produce recombinant VP2 protein of all nine serotypes for induction of nAbs.",
            "startOffset": 25109,
            "title": "Discussion"
        },
        {
            "endOffset": 31040,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Importantly, undesirable events such as reversion to virulence and reassortment between LAVs or with field virus are highly likely.",
            "startOffset": 30909,
            "title": "Discussion"
        },
        {
            "endOffset": 12810,
            "parents": [],
            "refoffsets": {
                "bib0065": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0070": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0080": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0090": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0095": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0110": {
                    "endOffset": 12809,
                    "startOffset": 12787
                },
                "bib0120": {
                    "endOffset": 12809,
                    "startOffset": 12787
                }
            },
            "secId": "sec0005",
            "sentence": "Vaccination with recombinant VP2 of AHSV serotype 4, 5 or 9 has been reported to induce nAbs and protect horses against homologous AHSV challenge infection [13,14,16,18,19,22,24].",
            "startOffset": 12631,
            "title": "Introduction"
        },
        {
            "endOffset": 17028,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Nine groups were immunized with VP2 protein from each AHSV serotype, two groups were immunized with cocktails of different combinations of VP2 proteins (one consisting of serotypes 1, 3, 7, 8 and other, serotypes of 2, 4, 5, 6, 9, respectively) and one group was immunized with phosphate buffered saline (PBS).",
            "startOffset": 16718,
            "title": "Immunization of soluble VP2 in guinea pigs"
        },
        {
            "endOffset": 14199,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0130": {
                    "endOffset": 14198,
                    "startOffset": 14194
                }
            },
            "secId": "sec0020",
            "sentence": "Genome segment 2 of AHSV serotypes 2, 4, 5 and 6, encoding VP2 were obtained from viral dsRNA according to the previously described method [26].",
            "startOffset": 14055,
            "title": "Preparation of recombinant AHSV VP2 protein"
        },
        {
            "endOffset": 12527,
            "parents": [],
            "refoffsets": {
                "bib0055": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0060": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0065": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0070": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0075": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0080": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0085": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0090": {
                    "endOffset": 12526,
                    "startOffset": 12519
                },
                "bib0095": {
                    "endOffset": 12526,
                    "startOffset": 12519
                }
            },
            "secId": "sec0005",
            "sentence": "To overcome safety issues, alternative AHS vaccines are under development including inactivated virus, recombinant VP2, DNA vaccine and vaccinia virus vectors expressing VP2 protein [11\u201319].",
            "startOffset": 12337,
            "title": "Introduction"
        },
        {
            "endOffset": 16149,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "After heating at 95 \u00b0C for 1 min, the samples were analyzed by SDS-PAGE with BSA as concentration standard and protein molecular weight standard (Page Ruler, SM0671, Fermentas).",
            "startOffset": 15972,
            "title": "Preparation of soluble VP2 protein"
        },
        {
            "endOffset": 27860,
            "parents": [],
            "secId": "sec0070",
            "sentence": "To avoid eliciting non-neutralizing Abs, expression and immunization of only neutralization domain of VP2 may help to induce nAbs more efficiently.",
            "startOffset": 27713,
            "title": "Discussion"
        },
        {
            "endOffset": 22845,
            "parents": [
                {
                    "id": "sec0050",
                    "title": "Results"
                }
            ],
            "secId": "sec0060",
            "sentence": "However, these cross-reactive nAb titers are >40 times lower than the nAb titer against the respective homologous serotypes used for immunization.",
            "startOffset": 22699,
            "title": "Immunogenicity of AHSV VP2 proteins in guinea pigs"
        },
        {
            "endOffset": 28996,
            "parents": [],
            "secId": "sec0070",
            "sentence": "This might suggest a negative interference between some of the VP2 proteins in cocktails to induce nAbs.",
            "startOffset": 28892,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X14009578",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Yuta",
                "initial": "Y.",
                "last": "Kanai"
            },
            {
                "email": null,
                "first": "Piet A.",
                "initial": "P.A.",
                "last": "van Rijn"
            },
            {
                "email": null,
                "first": "Mieke",
                "initial": "M.",
                "last": "Maris-Veldhuis"
            },
            {
                "email": null,
                "first": "Yuki",
                "initial": "Y.",
                "last": "Kaname"
            },
            {
                "email": null,
                "first": "T. N.",
                "initial": "T.N.",
                "last": "Athmaram"
            },
            {
                "email": "polly.roy@lshtm.ac.uk",
                "first": "Polly",
                "initial": "P.",
                "last": "Roy"
            }
        ],
        "doi": "10.1016/j.vaccine.2014.07.031",
        "firstpage": "4932",
        "issn": "0264410X",
        "keywords": [
            "African horse sickness",
            "Capsid protein VP2",
            "Recombinant protein",
            "Subunit vaccine"
        ],
        "lastpage": "4937",
        "openaccess": "Full",
        "pub_year": 2014,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus"
    }
}